Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study-Reference-Cited by-同舟云学术

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Published:2024-01 Issue:1 Volume:11 Page:e15-e26
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Garcia-Manero Guillermo,McCloskey James,Griffiths Elizabeth A,Yee Karen W L,Zeidan Amer M,Al-Kali Aref,Deeg H Joachim,Patel Prapti A,Sabloff Mitchell,Keating Mary-Margaret,Zhu Nancy,Gabrail Nashat Y,Fazal Salman,Maly Joseph,Odenike Olatoyosi,Kantarjian Hagop,DeZern Amy E,O’Connell Casey L,Roboz Gail J,Busque Lambert,Buckstein Rena,Amin Harshad,Randhawa Jasleen,Leber Brian,Shastri Aditi,Dao Kim-Hien,Oganesian Aram,Hao Yong,Keer Harold N,Azab Mohammad,Savona Michael R

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. Myelodysplastic Syndromes;Cazzola;N Engl J Med,2020

2. NCCN Guidelines® Insights: Myelodysplastic syndromes, version 3.2022;Greenberg;J Natl Compr Canc Netw,2022

3. Molecular international prognostic scoring system for myelodysplastic syndromes;Bernard;NEJM Evidence,2022

4. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up;Cabrero;Leuk Res,2015

5. Injectable hypomethylating agents for management of myelodysplastic syndromes: patients' perspectives on treatment;Zeidan;Clin Lymphoma Myeloma Leuk,2022

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08

4. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome;Current Treatment Options in Oncology;2024-05-30

5. Role of reactive oxygen species in myelodysplastic syndromes;Cellular & Molecular Biology Letters;2024-04-14